MX2009005925A - Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso. - Google Patents
Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso.Info
- Publication number
- MX2009005925A MX2009005925A MX2009005925A MX2009005925A MX2009005925A MX 2009005925 A MX2009005925 A MX 2009005925A MX 2009005925 A MX2009005925 A MX 2009005925A MX 2009005925 A MX2009005925 A MX 2009005925A MX 2009005925 A MX2009005925 A MX 2009005925A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- phosphoinositide
- kinase inhibitor
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Los compuestos de las Fórmulas Ia-d, donde X es S o O, mor es un grupo morfolino, y R3 es un grupo heteroarilo monocíclico e incluyendo los estereoisómeros, los isómeros geométricos. Los tautómeros, los solvatos, los metabolitos y las sales farmacéuticamente aceptables de él, son útiles para la modulación de la actividad de lípido quinasas incluyendo PI3K, y para el tratamiento de trastornos tales como el cáncer mediado por lípido quinasas. Se revelan los métodos para usar los compuestos de la Fórmula Ia-d para los diagnósticos in vivo, in situ e in vivo, la prevención o el tratamiento de tales trastornos en las células de mamíferos, o las condiciones patológicas. (ver fórmulas (Ic e Id)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87342206P | 2006-12-07 | 2006-12-07 | |
PCT/US2007/086533 WO2008073785A2 (en) | 2006-12-07 | 2007-12-05 | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009005925A true MX2009005925A (es) | 2009-08-12 |
Family
ID=39403189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009005925A MX2009005925A (es) | 2006-12-07 | 2007-12-05 | Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9487533B2 (es) |
EP (1) | EP2114950B1 (es) |
JP (1) | JP5500990B2 (es) |
KR (1) | KR101507182B1 (es) |
CN (1) | CN101675053B (es) |
AR (1) | AR064154A1 (es) |
AU (1) | AU2007333243B2 (es) |
BR (1) | BRPI0717907A2 (es) |
CA (1) | CA2671845C (es) |
CL (1) | CL2007003523A1 (es) |
ES (1) | ES2571028T3 (es) |
IL (1) | IL199151A (es) |
MX (1) | MX2009005925A (es) |
NO (1) | NO342697B1 (es) |
PE (1) | PE20081353A1 (es) |
RU (1) | RU2470936C2 (es) |
TW (1) | TW200829594A (es) |
WO (1) | WO2008073785A2 (es) |
ZA (1) | ZA200904531B (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1577816A3 (en) * | 1996-09-04 | 2006-08-02 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce and rights management |
AU2007329352B2 (en) | 2006-12-07 | 2013-01-17 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
JP5539190B2 (ja) * | 2007-06-12 | 2014-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾロピリミジン類及びホスファチジルイノシトール−3キナーゼのインヒビターとしてのそれらの使用 |
CN101939006B (zh) * | 2007-09-12 | 2015-09-16 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法 |
CN101932587A (zh) * | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
CN101909631B (zh) * | 2007-10-25 | 2012-09-12 | 健泰科生物技术公司 | 制备噻吩并嘧啶化合物的方法 |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
JP5520831B2 (ja) | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
JP2011529920A (ja) * | 2008-07-31 | 2011-12-15 | ジェネンテック, インコーポレイテッド | ピリミジン化合物、組成物及び使用方法 |
JPWO2010027002A1 (ja) * | 2008-09-05 | 2012-02-02 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環モルホリン誘導体 |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
JP2012505836A (ja) | 2008-10-17 | 2012-03-08 | アカール ファーマ ピーティーワイ リミテッド | S1p受容体モジュレーターおよびそれらの使用 |
WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
JP5452617B2 (ja) * | 2009-01-08 | 2014-03-26 | キュリス,インコーポレイテッド | 亜鉛結合部分を有するホスホイノシチド3−キナーゼインヒビター |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
KR101781654B1 (ko) * | 2009-03-12 | 2017-09-25 | 제넨테크, 인크. | 조혈 악성종양의 치료를 위한 포스포이노시티드 3-키나제 억제제 화합물 및 화학요법제의 조합물 |
JP5647998B2 (ja) * | 2009-03-13 | 2015-01-07 | カトリーケ ユニバーシテイト ルーヴェン、ケー.ユー. ルーヴェン アール アンド ディー | 免疫抑制剤としてのチアゾロピリミジン調節因子 |
US8785651B2 (en) | 2009-03-24 | 2014-07-22 | Sumitomo Chemical Company, Limited | Method for manufacturing a boronic acid ester compound |
CN102459272B (zh) | 2009-05-27 | 2014-08-06 | 健泰科生物技术公司 | 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法 |
SG182247A1 (en) * | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
JP2012531422A (ja) * | 2009-06-24 | 2012-12-10 | ジェネンテック, インコーポレイテッド | オキソ−複素環縮合ピリミジン化合物、組成物及び使用方法 |
JP5546636B2 (ja) | 2009-09-28 | 2014-07-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾキセピンpi3k阻害剤化合物及び使用方法 |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
KR101821768B1 (ko) | 2009-11-05 | 2018-01-24 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 벤조피란 키나제 조절제 |
KR101447789B1 (ko) * | 2009-11-12 | 2014-10-06 | 에프. 호프만-라 로슈 아게 | N-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법 |
EP2498780B1 (en) * | 2009-11-12 | 2016-09-07 | F.Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
CN102762565A (zh) | 2010-02-22 | 2012-10-31 | 弗·哈夫曼-拉罗切有限公司 | 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法 |
CN102970868A (zh) * | 2010-04-16 | 2013-03-13 | 柯瑞斯公司 | 具有k-ras突变的癌症的治疗 |
AU2011269989B2 (en) * | 2010-06-23 | 2014-12-11 | Hanmi Science Co., Ltd. | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
KR101531117B1 (ko) | 2010-07-14 | 2015-06-23 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대해 선택적인 퓨린 화합물, 및 사용 방법 |
DE102010049595A1 (de) * | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
CN103313989B (zh) | 2010-12-16 | 2016-05-04 | 霍夫曼-拉罗奇有限公司 | 三环pi3k抑制剂化合物和使用方法 |
WO2012103524A2 (en) * | 2011-01-27 | 2012-08-02 | The Trustees Of Princeton University | Inhibitors of mtor kinasa as anti- viral agents |
CA2825028A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
WO2012122383A2 (en) * | 2011-03-09 | 2012-09-13 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
EP2688891B1 (en) | 2011-03-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
US8710219B2 (en) | 2011-04-01 | 2014-04-29 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
ES2786569T3 (es) | 2011-04-08 | 2020-10-13 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para el tratamiento de infecciones víricas |
CN107337659A (zh) | 2011-05-04 | 2017-11-10 | 理森制药股份公司 | 作为蛋白激酶调节剂的新颖化合物 |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
PL2776439T3 (pl) | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Pochodne puryny do leczenia zakażeń wirusowych |
CN104053661B (zh) | 2011-11-23 | 2018-06-19 | 癌症研究技术有限公司 | 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂 |
US9499561B2 (en) | 2012-04-10 | 2016-11-22 | Shanghai Yingli Pharmaceutical Co., Ltd. | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof |
JP6301316B2 (ja) | 2012-05-23 | 2018-03-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法 |
CN104379163A (zh) | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
DK3260455T3 (da) | 2012-07-04 | 2019-06-11 | Rhizen Pharmaceuticals S A | Selektive pi3k delta-hæmmere |
AU2013288600B2 (en) | 2012-07-13 | 2017-06-29 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections |
BR112015007970A8 (pt) | 2012-10-10 | 2019-08-27 | Hoffmann La Roche | processo de preparação de (s)-1-(4-((2-(2-aminopirimidin-5-il)-7-metil-4-morfolinotieno[3,2-d]pirimidin-6-il)metil)piperazin-1-il)-2-hidroxipropan-1-ona e sal de oxalato de (s)-2-hidróxi-1- (piperazin-1-il)propan-1-ona |
NZ705589A (en) | 2012-10-10 | 2019-05-31 | Janssen Sciences Ireland Uc | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
UA118341C2 (uk) | 2012-11-16 | 2019-01-10 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій |
MX367915B (es) | 2013-02-21 | 2019-09-11 | Janssen Sciences Ireland Uc | Derivados de 2-aminopirimidina para el tratamiento de infecciones viricas. |
EP2978429B1 (en) | 2013-03-29 | 2017-02-22 | Janssen Sciences Ireland UC | Macrocyclic deaza-purinones for the treatment of viral infections |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
CN105377833B (zh) | 2013-05-24 | 2018-11-06 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的吡啶酮衍生物 |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
EA202090258A3 (ru) | 2013-06-27 | 2020-07-31 | Янссен Сайенсиз Айрлэнд Юси | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний |
KR102322425B1 (ko) | 2013-07-30 | 2021-11-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체 |
EP3053926B1 (en) | 2013-09-30 | 2018-08-08 | Shanghai Yingli Pharmaceutical Co. Ltd. | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2015190316A1 (ja) * | 2014-06-09 | 2015-12-17 | 住友化学株式会社 | ピリジン化合物の製造方法 |
TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類 |
KR20160082062A (ko) | 2014-12-30 | 2016-07-08 | 한미약품 주식회사 | 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체 |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
KR20180012324A (ko) | 2015-06-29 | 2018-02-05 | 에프. 호프만-라 로슈 아게 | 타셀리십을 사용하는 치료 방법 |
CN106467545B (zh) * | 2015-08-20 | 2018-10-16 | 北大方正集团有限公司 | 一种噻吩并嘧啶化合物 |
WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
CN109311880B (zh) | 2016-06-29 | 2021-09-03 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的新的四氢吡啶并嘧啶类化合物 |
US11053256B2 (en) | 2016-07-01 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
KR102450287B1 (ko) | 2016-09-29 | 2022-09-30 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그 |
CN110573518A (zh) | 2017-01-26 | 2019-12-13 | 尤拉·S·赞特里佐斯 | 被取代的双环嘧啶基化合物及其组合物和用途 |
CN107163061A (zh) * | 2017-04-14 | 2017-09-15 | 江西科技师范大学 | 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用 |
MA49458A (fr) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
CA3112177A1 (en) | 2018-09-11 | 2020-03-19 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
CN109540859B (zh) * | 2018-11-27 | 2021-02-09 | 上海交通大学 | 一种水体中抗生素的分析和含量预测方法 |
CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
CN115135659B (zh) * | 2021-01-15 | 2024-03-12 | 深圳微芯生物科技股份有限公司 | 一类吗啉衍生物及其制备方法和应用 |
CN116262758A (zh) * | 2021-12-15 | 2023-06-16 | 上海博悦生物科技有限公司 | 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途 |
CN114539293B (zh) * | 2022-02-24 | 2023-09-22 | 广东晨康生物科技有限公司 | 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
DE2050814A1 (de) * | 1970-10-16 | 1972-04-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen |
BE759493A (fr) * | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
DE1959403A1 (de) | 1969-11-26 | 1971-06-03 | Thomae Gmbh Dr K | Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
DE2058085A1 (de) * | 1970-11-26 | 1972-05-31 | Thomae Gmbh Dr K | Neues Verfahren zur Herstellung von 4-Morpholino-thieno[3,2-d]pyrimidinen |
RO62428A (fr) * | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
CH592668A5 (es) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4196207A (en) * | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
RU1391052C (ru) * | 1986-08-25 | 1993-11-30 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью |
US5075305A (en) * | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
CA2407593C (en) | 2000-04-27 | 2011-01-11 | Yamanouchi Pharmaceutical Co. Ltd. | Fused heteroaryl derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
CN1458933A (zh) * | 2000-09-29 | 2003-11-26 | 日本曹达株式会社 | 噻吩并嘧啶化合物及其盐以及其制备方法 |
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
WO2006004601A1 (en) * | 2004-06-03 | 2006-01-12 | Nordson Corporation | Color change for powder coating material application system |
US7557112B2 (en) * | 2004-10-08 | 2009-07-07 | Astellas Pharma Inc. | Aromatic-ring-fused pyrimidine derivative |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
EP2032582A1 (en) | 2006-04-26 | 2009-03-11 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as pi3k inhibitors |
RU2443706C2 (ru) | 2006-04-26 | 2012-02-27 | Дженентек, Инк. | Фармацевтические соединения |
WO2007127183A1 (en) * | 2006-04-26 | 2007-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
US7781433B2 (en) * | 2006-04-26 | 2010-08-24 | Piramed Limited | Pharmaceutical compounds |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
AU2007329352B2 (en) | 2006-12-07 | 2013-01-17 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
-
2007
- 2007-12-05 TW TW096146408A patent/TW200829594A/zh unknown
- 2007-12-05 CN CN200780051049.8A patent/CN101675053B/zh active Active
- 2007-12-05 US US11/951,189 patent/US9487533B2/en active Active
- 2007-12-05 WO PCT/US2007/086533 patent/WO2008073785A2/en active Application Filing
- 2007-12-05 ES ES07865255T patent/ES2571028T3/es active Active
- 2007-12-05 CA CA2671845A patent/CA2671845C/en not_active Expired - Fee Related
- 2007-12-05 CL CL200703523A patent/CL2007003523A1/es unknown
- 2007-12-05 EP EP07865255.9A patent/EP2114950B1/en active Active
- 2007-12-05 BR BRPI0717907-3A2A patent/BRPI0717907A2/pt not_active Application Discontinuation
- 2007-12-05 JP JP2009540457A patent/JP5500990B2/ja active Active
- 2007-12-05 AR ARP070105448A patent/AR064154A1/es unknown
- 2007-12-05 MX MX2009005925A patent/MX2009005925A/es active IP Right Grant
- 2007-12-05 ZA ZA200904531A patent/ZA200904531B/xx unknown
- 2007-12-05 AU AU2007333243A patent/AU2007333243B2/en not_active Ceased
- 2007-12-05 PE PE2007001727A patent/PE20081353A1/es not_active Application Discontinuation
- 2007-12-05 RU RU2009125916/04A patent/RU2470936C2/ru not_active IP Right Cessation
- 2007-12-05 KR KR1020097014132A patent/KR101507182B1/ko active IP Right Grant
-
2009
- 2009-06-04 IL IL199151A patent/IL199151A/en not_active IP Right Cessation
- 2009-07-06 NO NO20092565A patent/NO342697B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101507182B1 (ko) | 2015-03-30 |
CN101675053A (zh) | 2010-03-17 |
ZA200904531B (en) | 2010-09-29 |
AU2007333243B2 (en) | 2013-03-14 |
WO2008073785A3 (en) | 2008-08-28 |
KR20090106508A (ko) | 2009-10-09 |
TW200829594A (en) | 2008-07-16 |
NO342697B1 (no) | 2018-07-09 |
JP5500990B2 (ja) | 2014-05-21 |
PE20081353A1 (es) | 2008-11-12 |
CL2007003523A1 (es) | 2008-08-22 |
AR064154A1 (es) | 2009-03-18 |
CN101675053B (zh) | 2014-03-12 |
RU2470936C2 (ru) | 2012-12-27 |
IL199151A (en) | 2017-01-31 |
RU2009125916A (ru) | 2011-01-20 |
AU2007333243A1 (en) | 2008-06-19 |
CA2671845A1 (en) | 2008-06-19 |
JP2010512337A (ja) | 2010-04-22 |
ES2571028T3 (es) | 2016-05-23 |
US20080269210A1 (en) | 2008-10-30 |
NO20092565L (no) | 2009-09-07 |
IL199151A0 (en) | 2010-03-28 |
CA2671845C (en) | 2015-03-24 |
BRPI0717907A2 (pt) | 2013-11-05 |
EP2114950B1 (en) | 2016-03-09 |
EP2114950A2 (en) | 2009-11-11 |
US9487533B2 (en) | 2016-11-08 |
WO2008073785A2 (en) | 2008-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009005925A (es) | Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso. | |
MX2009005950A (es) | Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso. | |
TW200801012A (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use | |
MX2010002543A (es) | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. | |
SG10201407781SA (en) | Benzoxepin PI3K Inhibitor Compounds And Methods Of Use | |
MX2011009167A (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. | |
MX2010010659A (es) | Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos. | |
WO2007127175A3 (en) | Pharmaceutical compounds | |
WO2007027855A3 (en) | Raf inhibitor compounds and methods of use thereof | |
MX2011012520A (es) | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. | |
AU2009312464A8 (en) | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | |
WO2009111278A3 (en) | Raf inhibitor compounds and methods of use thereof | |
PH12013501779A1 (en) | Pyrrolopyridines as kinase inhibitors | |
MX2008011220A (es) | Compuestos de pirazol heterobiciclicos y metodos de uso. | |
NO20083114L (no) | Polysykliske indazolderivater som er ERK-inhibitorer | |
SG151286A1 (en) | 5-substituted-2-phenylamino-benzamide as mek inhibitor | |
BR112013014914A2 (pt) | composto, composição farmacêutica, método de tratar câncer em um paciente e uso | |
NO20076553L (no) | RAF-inhibitorforbindelser og fremgangsmater for anvendelse derav | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
UA111756C2 (uk) | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона | |
WO2008028141A3 (en) | Raf inhibitor compounds and methods of use thereof | |
SG178899A1 (en) | Raf inhibitor compounds and methods of use thereof | |
WO2007109251A3 (en) | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | |
MX2011011764A (es) | Compuestos de carboxamida y su uso como inhibidores de calpaina. | |
NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |